US 11,786,511 B2
Methods for increasing circulating mesenchymal stem cells
Kevin J. Gaffney, Los Angeles, CA (US); Kathleen E. Rodgers, Los Angeles, CA (US); Maira Soto, Los Angeles, CA (US); and Michael Weinberg, Los Angeles, CA (US)
Assigned to University of Southern California, Los Angeles, CA (US)
Appl. No. 16/638,000
Filed by Kevin J. Gaffney, Los Angeles, CA (US); Kathleen E. Rodgers, Los Angeles, CA (US); Maira Soto, Los Angeles, CA (US); and Michael Weinberg, Los Angeles, CA (US)
PCT Filed Aug. 9, 2018, PCT No. PCT/US2018/045935
§ 371(c)(1), (2) Date Feb. 10, 2020,
PCT Pub. No. WO2019/036267, PCT Pub. Date Feb. 21, 2019.
Claims priority of provisional application 62/546,256, filed on Aug. 16, 2017.
Prior Publication US 2020/0215037 A1, Jul. 9, 2020
Int. Cl. A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/427 (2013.01) [A61K 31/4439 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01)] 7 Claims
 
1. A method for increasing circulating mesenchymal stem cells (MSC) in a subject, comprising administering to a subject in need thereof an amount effective to increase circulating MSC to a therapeutically valuable level in the subject of a compound of formula 7, 8, 9, 10, or 11 or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein the subject has a disorder selected from the group consisting of osteoarthritis, aplastic anemia, autoimmune hemolytic anemia, dermatomyositis, Graves' disease, idiopathic thrombocytopenic purpura, pemphigus/pemphigoid, polyarteritis nodosa, psoriasis, Sjögren's syndrome, granulomatosis with polyangiitis, and organ rejection, and wherein the method serves to treat the disorder.